Article Sidebar
Views pdf: 75
EXPRESSION OF p16 AND Ki67 PROTEINS IN PANCREATIC DUCTAL ADENOCARCINOMA
Main Article Content
Abstract
Objective: To investigate the expression of p16 and Ki67 proteins using immunohistochemical staining in patients with pancreatic ductal carcinoma. To investigate the correlation between the expression of p16 and Ki67 and the histopathological subtypes, differentiation, and histological grade. To analyze survival time according to the expression of p16 and Ki67. Material and method: Case series of 43 cases of pancreatic ductal adenocarcinoma operated at Cho Ray Hospital from March 2017 to December 2022. Results: The rate of p16 negativity is 60.5%. The average Ki67 index is 14.5%±1.6%. There is no correlation between p16 expression and histopathological subtypes (p=0.99), differentiation (p=0.99), or histological grade (p=0.99). There are correlations between Ki67 expression and differentiation (p=0.01) or histological grade (p=0.01). There is no correlation between Ki67 expression and histopathological subtypes (p=0.53). The average survival time after surgery for patients in the study is 18.6±2.2 months. The study did not show a significance correlation between average survival time and p16 expression (p=0.49) or Ki67 (p=0.48). Conclusion: The expression of p16 and Ki67 proteins in the Vietnamese patient group is within the range of data from studies worldwide. The mean Ki67 index increases with poorer differentiation and higher histological grade. This study did not show any correlation between p16 and Ki67 expression with survival time.
Article Details
Keywords
Pancreatic ductal adenocarcinoma, p16, Ki67, differentiation, histological grade, conventional, adenosquamous, colloid, survival time
References
2. Qian Y, Gong Y, Fan Z, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Journal of hematology and oncology. 2020; 13(1):130.
3. Hruban RH, Boffetta P, Hiraoka N. Ductal adenocarcinoma of the pancreas. Bosman FT, Carbciro F, Hruban RH, et al. WHO Classification of Tumours – Digestive System Tumours. 4th edition. International Agency for Research on Cancer; 2010: 281-291.
4. Ohtsubo K, Watanabe H, Yamaguchi Y, et al. Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. Journal of Gastroenterology. 2003; 38(7): 663-671.
5. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. International journal of cancer. 2000; 89(6): 469-474.
6. Oshima M, Okano K, Muraki S, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, SMAD4/DPC4) strongly predicts survival in patients with resected pancreatic cancer. Annals of Surgery. 2013; 258 (2): 336-346.
7. Masetti M, Acquaviva G, Visani M, et al. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53, and SMADS. Cancer Biomarkers: a section of disease markers. 2018; 21 (2): 323-334.
8. Lebe B, Sagol O, Ulukus C, et al. The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathology, research and practice. 2004; 200(5): 389-396.
9. Pergolini I, Crippa S, Pagnanelli M, et al. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. BJS Open. 2019; 3(5): 646-655.
10. Goitia-Duran MB, Linhares MM, Neto RA, et al. Expression of p53, p16 and Ki67 proteins in ductal adenocarcinoma of the pancreatic head and their relation with survivial and cell differentiation. Einstein (Sao Paulo). 2010; 8(4): 444-448.